MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating
patients with unresectable or metastatic refractory solid tumor, Hodgkin's lymphoma, or
non-Hodgkin's lymphoma.